Table 1.
Patient characteristics grouped by age.
| 35–44 yr | 45–54 yr | 55–64 yr | 65–74 yr | P | |
|---|---|---|---|---|---|
| Gleason score | 0.00 | ||||
| 6 | 51 (46.8) | 708 (35.4) | 1,919 (27.4) | 968 (18.5) | |
| 7 | 50 (45.9) | 1,027 (51.4) | 3,704 (53) | 2,949 (56.4) | |
| 8–10 | 2 (1.8) | 130 (6.5) | 679 (9.7) | 819 (15.7) | |
| Unknown | 6 (5.5) | 133 (6.7) | 689 (9.9) | 490 (9.4) | |
| Stage | 0.00 | ||||
| T1/T2 | 90 (82.6) | 1,510 (75.6) | 4,790 (68.5) | 3,209 (61.4) | |
| T3/4 | 19 (17.4) | 467 (23.4) | 2,131 (30.5) | 1,960 (37.5) | |
| Median PSA | 6.2 (2.2–14) | 6.3 (0.3–75) | 6.6 (0.2–95) | 6.4 (0.4–96) | NS |
| Location | |||||
| Metropolitan | 86 (78.9) | 1,504 (75.4) | 5,145 (73.7) | 3,892 (74.5) | NS |
| Rural | 23 (21.1) | 490 (24.6) | 1,836 (26.3) | 1,329 (25.5) | |
| Overall deaths | 2 | 47 | 262 | 329 | – |
| PC deaths | 1 | 16 | 58 | 58 | – |
NS, not significant, PC, prostate cancer; PSA, prostate-specific antigen.